Vicente Santa-Maria Lopez

Vicente Santa-Maria Lopez

Auto-generated profile, based on publicly available information

Vicente Santa-Maria Lopez

Department of Paediatric Oncology Hospital Sant Joan De Deu Barcelona Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Craig ErkerCraig Erker
Craig Erker
MMMartin Martin Mynarek
Martin Martin Mynarek
SBSimon Bailey
Simon Bailey
CMClaire M. Mazewski
Claire M. Mazewski
LBLorena V. Viviana Baroni
Lorena V. Viviana Baroni
LLLucie Lafay-Cousin
Lucie Lafay-Cousin
PURPOSE: Infant and young childhood medulloblastoma (iMB) is usually treated without craniospinal irradiation (CSI) to avoid neurocognitive late effects. Unfortunately, many children relapse. The purpose of this study was to assess salvage strategies and prognostic features of patients with iMB who relapse after CSI-sparing therapy. METHODS: We assembled a large international cohort of 380 patients with relapsed iMB, age younger than 6 years, and initially treated without CSI. Univariable and multivariable Cox models of postrelapse survival (PRS) were conducted for those treated with curative intent using propensity score analyses to account for confounding factors. RESULTS: The 3-year PRS, for 294 patients treated with curative intent, was 52.4% (95% CI, 46.4 to 58.3) with a median time to relapse from diagnosis of 11 months. Molecular subgrouping was available for 150 patients treated with curative intent, and 3-year PRS for sonic hedgehog (SHH), group 4, and group 3 were 60%, 84%, and 18% ( P = .0187), respectively. In multivariable analysis, localized relapse ( P = .0073), SHH molecular subgroup ( P = .0103), CSI use after relapse ( P = .0161), and age ≥ 36 months at initial diagnosis ( P = .0494) were associated with improved survival. Most patients (73%) received salvage CSI, and although salvage chemotherapy was not significant in multivariable analysis, its use might be beneficial for a subset of children receiving salvage CSI < 35 Gy ( P = .007). CONCLUSION: A substantial proportion of patients with relapsed iMB are salvaged after initial CSI-sparing approaches. Patients with SHH subgroup, localized relapse, older age at initial diagnosis, and those receiving salvage CSI show improved PRS. Future prospective studies should investigate optimal CSI doses and the role of salvage chemotherapy in this population.

1 March 2023 in JCO Precision Oncology
Verified
Journal Article
Closed access
NGNagore Gene-Olaciregui
Nagore Gene-Olaciregui
MPMarta Perez-Somarriba
Marta Perez-Somarriba
VSVicente Santa-María
Vicente Santa-María
OCOfelia Cruz
Ofelia Cruz
Soledad Gómez-GonzalezSoledad Gómez-Gonzalez
Soledad Gómez-Gonzalez
CLCinzia Lavarino
Cinzia Lavarino

8 October 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
MLMaria R. Pérez‐Torres Lobato
Maria R. Pérez‐Torres Lobato
MMMariona Morell
Mariona Morell
PSPalma Solano‐Páez
Palma Solano‐Páez
MOMarina Ortiz‐Palacios
Marina Ortiz‐Palacios
ÁMÁngela Menárgez
Ángela Menárgez
ALAnna Llort
Anna Llort

10 January 2023 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
NSNazaret Sánchez‐Sierra
Nazaret Sánchez‐Sierra
MPMarta Perez‐Somarriba
Marta Perez‐Somarriba
VSVicente Santa‐Maria
Vicente Santa‐Maria
OCOfelia Cruz
Ofelia Cruz
EGEnric García‐Rey
Enric García‐Rey
JMJulia Marsal
Julia Marsal

27 July 2024
Verified
Preprint
Open access
MLMaria Pérez-Torres Lobato
Maria Pérez-Torres Lobato
MDMariona Morell Daniel
Mariona Morell Daniel
PSPalma Solano-Páez
Palma Solano-Páez
MPMarina Ortiz Palacios
Marina Ortiz Palacios
ÁLÁngela Menárgez López
Ángela Menárgez López
ASAnna Llort Sales
Anna Llort Sales
Purpose: We aim to describe the characteristics of patients with childhood-onset craniopharyngioma and to analyze factors that impair quality of life (QoL) in this population. Methods: multicenter national study including patients treated between 2008-2022, from 2 to 25 years of age diagnosed with craniopharyngioma. QoL was assessed once during patient’s follow-up by age-adapted versions Pediatric Quality of Life Inventory (PedsQL TM ) questionnaire. Results: Sixty-six patients were included. Median age at diagnosis was 5 years (IQR 3-8), while median follow-up was 7.4 years (IQR 2.8-9.7). Most craniopharyngioma were suprasellar (93.9%) and 59.7% had hypothalamic involvement (HI). All patients underwent surgery, 44.4% received radiotherapy and 23.6%, intra-cystic therapy. Most frequent long-term complications were visual deficit (72.7%) and endocrine impairment (94.5%). Patients exhibited hypothyroidism requiring hormone replacement (92.4%), hypocortisolism (80.3%), diabetes insipidus (86.4%) and/or growth hormone therapy (50%). When parents evaluated QoL, PedsQL TM median score was 53.8 points out of 100 (IQR 41-71.6). Higher scores were noted when patients assessed their own QoL [median-score 64.8 (IQR 57.3-81.8)], observing statistical-significant differences (p=0.019). QoL was impaired by repeated surgeries (r -0.44; p=0.014), HI [median-score 51.5 (IQR 39-63.8) vs 76.4 (59-84.8); p=0.001], radiotherapy [median-score 51.9 (IQR 38.1-61.3) vs 63.8 (IQR 49-82.5); p=0.02] and longer follow-up (r-0.3; p=0.01). Conclusion: In our study, most patients had significant comorbidities and low overall QoL scores, which was mainly affected by repeated surgery, radiation, and HI. The complex management of these patients requires multidisciplinary teams that can warrant the hypothalamic preservation and prompt intervention to prevent and identify sequelae.

12 January 2026 in Neuro-Oncology Advances
Verified
Journal Article
Open access
GNGunther Nussbaumer
Gunther Nussbaumer
ONOlga Nigro
Olga Nigro
ABAnke Barnbrock
Anke Barnbrock
MBMartin Benesch
Martin Benesch
VBVeronica Biassoni
Veronica Biassoni
CVChiara Valentini
Chiara Valentini
Background: Diffuse intrinsic pontine glioma (DIPG) remains uniformly lethal. Stereotactic biopsy confirms the diagnosis and enables molecular profiling. Metastasis along the biopsy track (BTM) has been reported only anecdotally; its prevalence, clinical relevance, and implications for treatment remain unclear. Methods: A multicenter retrospective study in patients with confirmed DIPG and BTM was conducted based on central neuroradiologic review. Radiotherapy schedules were re-assessed to evaluate the feasibility of upfront biopsy track irradiation. Results: Ten children met inclusion criteria (median age 6.8 years). Biopsy route was supratentorial in six and infratentorial in four children, and side-cutting needles were used predominantly. H3F3A mutations were most frequent (n = 8); TP53 alterations were common in tumors with extended molecular profiling available. Median PFS was 8.1 months. Five patients each developed BTM prior to (median 2.7 months) or concurrently with progression of primary tumor. There was no difference in overall survival (median OS 12.0 months) compared with the reference cohort. Estimated BTM prevalence among biopsied DIPG from additional registry data was between 6.9% and 13.0%. Primary biopsy track irradiation proved to be feasible, and comparing the surgical access routes, the infratentorial biopsy track hardly increased radiation exposure of the whole brain. Conclusions: Needle track metastasis is a rare progression pattern in stereotactic biopsied DIPG. Upfront irradiation of the biopsy track may represent a strategy to mitigate the potential risk of BTM. From a dosimetric perspective, an infratentorial approach may therefore be considered, as it was associated with only marginally increased radiation exposure.